Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years

Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and safety of baricitinib in pediatric patients aged 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Atopic dermatitis
pediatric
baricitinib
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2411834
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items